Cervical Cancer – Drug Pipeline Landscape, 2023
Cervical cancer arises from the cells of the cervix. It is due to the abnormal growth of cells that have the ability to invade or spread to other parts of the body. There are two types of cervical cancer. They are squamous cell carcinomas, the cells that develop from the ectocervix, and adenocarcinomas, cells that develop in the glandular cells of the endocervix.
Cervical cancers are caused by the virus HPV, a sexually transmitted infection. HIV infection is also a risk factor. However, not all causes of cervical cancer are known. Cigarette smoking increase the risk of cancer, long-term use of oral contraceptives is also associated, and also having many pregnancies is associated with an increased risk of cervical cancer.
The early stages of cervical cancer are free of symptoms. Vaginal bleeding, contact bleeding, or a vaginal mass may indicate the presence of malignancy. Moderate pain during sexual intercourse and vaginal discharge; loss of appetite; weight loss; fatigue; pelvic pain; back pain; leg pain; leakage of urine or feces from the vagina.
Cervical cancer diagnosis involves screening tests, including a pap test and an HPV DNA test. The confirmation of the diagnosis of cervical cancer or precancer requires a biopsy of the cervix. Imaging tests also include ultrasound, CT scans, and MRIs.
Cervical cancer treatment includes radiation, chemotherapy, surgery, targeted therapy, and immunotherapy. Early stages can be treated with a radical hysterectomy with the removal of the lymph nodes. Larger early-stage tumors may be treated with radiation therapy and cisplatin-based chemotherapy, and advanced-stage tumors are treated with radiation therapy and cisplatin-based chemotherapy.
The pipeline of Cervical Cancer treatment market consists of a great variable of drugs. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) Antagonists, Angiopoietin-like 3 (ANGPTL3) Inhibitors, Thyroid Hormone Receptor-Beta agonist, and some others are the most highlighted class of this indication. Ongoing research and current trials have the potential to change the market.
More than 50 key players, including pharma giants such as Jiangsu Hengrui Pharmaceuticals Co Ltd, AstraZeneca, Sorrento Therapeutics Inc, Roche, Seagen, Merck, and others are working to bring novel therapies that overcome the roadblocks of Cervical Cancer treatment pipeline.
Global Insight Service’s, “Cervical Cancer – Drug Pipeline Landscape, 2023,” an overview of the Cervical Cancer pipeline drugs. This report covers detailed insights on Cervical Cancer drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to gain insights and thus help industry participants for decision making. Cervical Cancer pipeline report helps gaining insights on drugs which are under development stage of drug development process across globally. Global Insight Services aims to cover all the drug attributes, deals, regulatory milestones and all the upcoming milestones.
In January 2023, TScan Therapeutics Inc received U.S. FDA clearance for its investigational new drug (IND) application for TSC-204.
In December 2022, Hengrui announced the results of the Phase II clinical study of camrelizumab in combination with famitinib malate in the treatment of recurrent and metastatic cervical squamous cell carcinoma.
In December 2022, KangleGuard officially launched Phase III clinical study of the recombinant nine-valent human papillomavirus (HPV6/11/16/18/31/33/45/52/58) vaccine and enrolled the first subject in the Center for Disease Control and Prevention of Xing’an County, Guangxi Zhuang Autonomous Region.
In March 2022, HOOPIKA Pharma Inc announced a poster presentation entitled “HB-201 and HB-202, an arenavirus-based immunotherapy that induces tumor T cell infiltration in patients with HNSCC and other HPV16+ tumors” at the 2022 American Association for Cancer Research (AACR) Annual Meeting.
In November 2021, TCRCure received Investigational New Drug (IND) application clearance from the NMPA, China, for the Phase I/II clinical study of modified autologous T cells for targeting HPV and anti-PD-1 in the treatment of HPV-positive recurrence and metastasis cervical cancer.
QL1706 is under development for the treatment of persistent, recurrent, or metastatic cervical cancer. In December 2022, Qilu Pharmaceutical announced the results of the Phase II study of QL1706 in the first-line treatment of recurrent or metastatic cervical cancer.
(Balstilimab+Zalifrelimab) is under development for the treatment of advanced cervical cancer. In December 2021, Agenus announced the results in the Journal of Clinical Oncology (JCO) from a global Phase II clinical study of balstilimab (Bal) plus zalifreliamb (Zal) in second line (2L) recurrent/metastatic cervical cancer patients who had relapsed after treatment with platinum-based therapy.
De-TIL-0255 (NX-0255) is under development for the treatment of recurrent, metastatic, or persistent cervical carcinoma. In November 2021, Nurix Therapeutics Inc. announced the US FDA’s clearance of its Investigational New Drug (IND) application for De-TIL-0255 for the treatment of a range of solid tumors, including cervical cancer. In November 2022, Nurix Therapeutics Inc. presented preclinical data supporting the utility of CBL-B inhibitors to enhance cell therapy at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
HB-201 is under development for the treatment of locally adcanced cervical cancer. In July 2019, HOOPIKA Pharma Inc received IND clearance from US FDA for Phase I/II clinical trial of HB-201 for the treatment of human papilloma virus (HPV) positive cancers.
|QL1706||Qilu Pharmaceutical Co Ltd||Phase III||Monoclonal Antibody||Programmed Cell Death Protein 1 (PD-1), Cluster of Differentiation 152 (CD152 or CTLA-4); Programmed Cell Death Protein 1 (PD-1) Antagonist; Cluster of Differentiation 152 (CD152 or CTLA-4) Antagonist||Intravenous|
|(Balstilimab+Zalifrelimab)||Agenus Inc||Phase II||Monoclonal Antibody||Programmed Cell Death Protein 1 (PD-1), Cluster of Differentiation 152 (CD152 or CTLA-4); Programmed Cell Death Protein 1 (PD-1) Antagonist; Cluster of Differentiation 152 (CD152 or CTLA-4) Antagonist||Intravenous|
|De-TIL-0255||Nurix Therapeutics Inc||Phase I||Small Molecule||Thyroid Hormone Receptor-Beta; Thyroid Hormone Receptor-Beta Agonist||Oral|
|HB-201||Hookipa Pharma Inc||Phase 0||Cellular Immunotherapies||Proprotein convertase subtilisin/kexin type 9 (PCSK9); Proprotein convertase subtilisin/kexin type 9 (PCSK9) Inhibitor||Intravenous|
Figure: Number of Drugs for The Treatment of Cervical Cancer Under Each Stage of Development
The research process includes extensive secondary research on public domain and other authentic sources carried out to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, clinical trials registries.
The pipeline landscape report consists of pipeline product based on several stages of development ranging from discovery to Pre-Registration. The report provides a review of pipeline therapeutics for Cervical Cancer by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of Cervical Cancer therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals and key upcoming milestones.
Reasons to Buy
Helps to find and recognize significant therapeutics under development for Cervical Cancer. Thorough understanding of Cervical Cancer pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge on competitor information, analysis, and insights.
Plan of collaborations from various industry partners that have role in some or the other stage of drug development like contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Frequently Asked Questions
• What is Cervical Cancer?
• What are the Causes, Signs and Symptoms of Cervical Cancer?
• How is Cervical Cancer diagnosed?
• What are the most common treatments available for Cervical Cancer?
• How many/which companies are developing Cervical Cancer drugs?
• How many Cervical Cancer drugs are under development by each company and their stage of development?
• How many emerging drugs are in late-stage, mid-stage and early-stage of development for the Cervical Cancer treatment?
• What are the key collaborations, mergers and acquisitions, licensing activities related to the Cervical Cancer therapeutics?
• What are the molecule types, target, mechanism of action and route of administration of emerging drugs under development for the treatment of Cervical Cancer?
• What are the clinical studies available for Cervical Cancer and their status?
• What are the key regulatory designations that have been granted to the treatment emerging drugs?
• What are the key upcoming milestones for Cervical Cancer drugs?
• How many drugs are under Inactive or Discontinued for the treatment of Cervical Cancer?
Table of Contents
List of Table
List of Figures
1.1 Cervical Cancer – Pipeline Drugs, 2023 – Coverage
2. Disease Overview – Cervical Cancer
2.2 Signs and Symptoms
2.4 Disease Management
3. Cervical Cancer – Pipeline Drugs Development – Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products Under Development by Companies, 2023
3.3 Products Under Development by Companies, 2023
4. Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.4 Assessment by Route of Administration
5. Drug Profiles
5.1 Clinical Stage Drugs – Phase III
5.1.5 Famitinib Malate
5.1.7 Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine
5.1.9 Tisotumab Vedotin
5.2 Clinical Stage Drugs – Phase II
5.3 Clinical Stage Drugs – Phase I
5.4 Clinical Stage Drugs – Phase 0
5.4.2 Tumor Infiltrating Lymphocytes
5.5 Early-Stage Drugs – IND/CTA Filed
5.6 Early-Stage Drugs – Preclinical
5.6.2 Drug for Cervical Cancer
5.7 Early-Stage Drugs – Discovery
5.8 Unknown Stage Drugs
6. Key Regulatory Designations
7. Key Deals
8. Key Upcoming Milestones
9. Key Companies Involved
9.1 Advenchen Laboratories LLC
9.2 Agenus Inc
9.3 Akeso Biopharma Co Ltd
9.4 Arcus Biosciences, Inc
9.6 Beijing Health Guard Biotechnology, Inc
9.7 EnhancedBio Inc
9.8 F. Hoffmann-La Roche Ltd
9.9 Genexine, Inc
9.10 Guangzhou Yuheng Biotechnology Co Ltd
9.11 Hangzhou Adlai Nortye Biopharma Co Ltd
9.12 Hangzhou Sumgen Biotech Co Ltd
9.13 Hookipa Pharma Inc
9.14 ImmunityBio, Inc
9.15 Jiangsu Hengrui Pharmaceuticals Co Ltd
9.16 Jiangsu Recbio Technology Co Ltd
9.18 Merck & Co Inc
9.19 Nurix Therapeutics, Inc
9.20 Nykode Therapeutics ASA
9.21 Qilu Pharmaceutical Co Ltd
9.22 Qingdao Huasai Berman Medical Cell Biology Co Ltd
9.23 Recbio Technology Co Ltd
9.24 Regeneron Pharmaceuticals Inc
9.25 Seagen Inc
9.26 Shanghai OriginCell Therapeutics Co Ltd
9.28 Sorrento Therapeutics Inc
9.29 TargImmune Therapeutics AG
9.30 TCR CURE Biopharma Technology Co Ltd
9.31 TScan Therapeutics Inc
9.32 Voltron Therapeutics Inc
9.33 Xencor Inc
10. Dormant Drugs
10.1 Inactive Drugs
10.2 Discontinued Drugs
List of Tables
Table 1.1 Number of Products Under Development by Cervical Cancer
Table 1.2 Number of Products Under Development by Companies
Table 1.3 Products Under Development by Companies
Table 1.4 Products by Targets
Table 1.5 Products by Mechanism of Action
Table 1.6 Products by Molecule Type
Table 1.7 Products by Route of Administration
Table 2.1 Clinical Trial Details – AK104/Akeso Biopharma Co Ltd
Table 2.2 Clinical Trial Details – AL3818/Advenchen Laboratories LLC
Table 2.3 Clinical Trial Details – Camrelizumab/Jiangsu Hengrui Pharmaceuticals Co Ltd
Table 2.4 Clinical Trial Details – Durvalumab/AstraZeneca
Table 2.5 Clinical Trial Details – Famitinib Malate/Jiangsu Hengrui Pharmaceuticals Co Ltd
Table 2.6 Clinical Trial Details – QL1706/Qilu Pharmaceutical Co Ltd
Table 2.7 Clinical Trial Details – Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine/Beijing Health Guard Biotechnology, Inc
Table 2.8 Clinical Trial Details – Tisotumab/ VedotinSeagen Inc
Table 2.9 Clinical Trial Details – (Balstilimab+Zalifrelimab)/Agenus Inc
Table 2.10 Clinical Trial Details – Cemiplimab/Regeneron Pharmaceuticals Inc
Table 2.11 Clinical Trial Details – GLS-010/Guangzhou Yuheng Biotechnology Co Ltd
Table 2.12 Clinical Trial Details – GX-188E/Genexine, Inc
Table 2.13 Clinical Trial Details – MK-7684A/Merck & Co Inc
Table 2.14 Clinical Trial Details – SG001/Hangzhou Sumgen Biotech Co Ltd
Table 2.15 Clinical Trial Details – TC-E202TCR/CURE Biopharma Technology Co Ltd
Table 2.16 Clinical Trial Details – TiragolumabF. Hoffmann-La Roche Ltd
Table 2.17 Clinical Trial Details – Tucatinib/Merck & Co Inc
Table 2.18 Clinical Trial Details – VB10.16/Nykode Therapeutics ASA
Table 2.19 Clinical Trial Details – AB308/Arcus Biosciences, Inc
Table 2.20 Clinical Trial Details – AN0025/Hangzhou Adlai Nortye Biopharma Co Ltd
Table 2.21 Clinical Trial Details – DeTIL-0255/Nurix Therapeutics, Inc
Table 2.22 Clinical Trial Details – SGN-ALPV/Seagen Inc
Table 2.23 Clinical Trial Details – SGN-B6A/Seagen Inc
Table 2.24 Clinical Trial Details – SGN-STN/VSeagen Inc
Table 2.25 Clinical Trial Details – XmAb23104/Xencor Inc
Table 3.1 Regulatory Designations
Table 4.1 Inactive Drugs
Table 4.2 Discontinued Drugs
List of Figures
Figure 1.1 Number of Products Under Development for Cervical Cancer, 2023
Figure 1.2 Products by Top 5 Targets and Stage of Development for Cervical Cancer, 2023
Figure 1.3 Products by Top 5 Mechanism of Action for Cervical Cancer, 2023
Figure 1.4 Products by Top 5 Molecule Type for Cervical Cancer, 2023
Figure 1.5 Products by Top 5 Route of Administration for Cervical Cancer, 2023
- Advenchen Laboratories LLC
- Agenus Inc
- Akeso Biopharma Co Ltd
- Arcus Biosciences, Inc
- Beijing Health Guard Biotechnology, Inc
- EnhancedBio Inc
- Hoffmann-La Roche Ltd
- Genexine, Inc
- Guangzhou Yuheng Biotechnology Co Ltd
- Hangzhou Adlai Nortye Biopharma Co Ltd
- Hangzhou Sumgen Biotech Co Ltd
- Hookipa Pharma Inc
- ImmunityBio, Inc
- Jiangsu Hengrui Pharmaceuticals Co Ltd
- Jiangsu Recbio Technology Co Ltd
- Merck & Co Inc
- Nurix Therapeutics, Inc
- Nykode Therapeutics ASA
- Qilu Pharmaceutical Co Ltd
- Qingdao Huasai Berman Medical Cell Biology Co Ltd
- Recbio Technology Co Ltd
- Regeneron Pharmaceuticals Inc
- Seagen Inc
- Shanghai OriginCell Therapeutics Co Ltd
- Sorrento Therapeutics Inc
- TargImmune Therapeutics AG
- TCR CURE Biopharma Technology Co Ltd
- TScan Therapeutics Inc
- Voltron Therapeutics Inc
- Xencor Inc
- Assessment by Stage of Development
- Assessment by Companies
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Molecule Type
- Assessment by Route of Administration